UPB Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -56.03%, SMA50 -68.31%, SMA200 -58.8%). The stock’s 14-day RSI is 19.04 (weak momentum), while the ATR of 1.95 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.54% below its high and over 53.7% above its low. Average 10-day trading volume of 793.85 thousand shares is slightly above the 3-month average of 618.74 thousand, indicating heightened recent market interest.

Wall Street analysts project EPS growth of 14.52% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $51.00 to $8.00. The high target offers 755.7% upside. The low target suggests 34.23% downside. The mean target is $36.25. This offers 508.22% upside. Upstream Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -6.41%. The prior quarter beat by -5.06%. Over the last six quarters, Apple has recorded several small beats. These include 4.08% in May 06, 2025.

Upstream Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.89. This means the shares are trading below this model’s fair value.

Upstream Bio, Inc. has 54.77 million shares outstanding. The public float is 42.81 million shares, elevated short interest at 10.24% of float. This equals 3.65 million shares. The short ratio is 7.67 days. Institutional investors hold 108.56% of the float. Insiders own 14.78%. Sutherland Everett Rand holds 70.81 thousand shares, Deykin Aaron has 33.20 thousand shares and GRAY MICHAEL has 28.80 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.03 thousand shares across 10 transactions.

Upstream Bio, Inc. (NASDAQ:UPB) closed at $5.96 USD, losing -$0.23 (-3.72%) from the previous close of $6.19. The stock is currently within 5% of its 52-week low $5.77 and $33.68. With a market capitalization of about $324.34 million, Upstream Bio, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.29). Key stats such as the average daily volume over the past year has been around 620.29 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Upstream Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO E. Rand Sutherland, the company employs approximately 75 people and listed since October 11, 2024. Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system.

Upstream Bio, Inc. trades at a P/E ratio of -2.01, slightly below the S&P 500 average, with a price-to-sales ratio of 100.66 and a price-to-book ratio of 1.18 suggesting the stock is closer to book value. The P/FCF stands at -2.33, also below market averages.

Upstream Bio, Inc. (NASDAQ:UPB) shares are up 14.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Upstream Bio, Inc. trading at a premium to the broader market with a P/E of -2.01. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $36.25, suggesting 508.22% upside. Our AI forecast model points to short-term weakness (-5.87% over two weeks), a medium-term fall (-62.92% over three months), and a longer-term loss (-83.89% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Upstream Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.87%, with price expected at $5.61 by September 22, 2026, within a range of $5.30 to $5.93 3-Month Outlook: Projected fall of -62.92%, reaching $2.21 by December 07, 2026, with a range of $1.50 to $2.75. 1-Year Outlook: Projected loss of -83.89%, with price at $0.96 by September 08, 2027, within a range of $0.00 to $0.00.